丙型肝炎病毒清除后的临床结局演变  

Evolution of clinical outcomes following hepatitis C virus clearance

作　　者：杨甲 饶慧瑛[1] Yang Jia;Rao Huiying(Peking University People's Hospital,Peking University Hepatology Institute,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases,Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis,Beijing 100044,China)

机构地区：[1]北京大学人民医院、北京大学肝病研究所、丙型肝炎和肝病免疫治疗北京市重点实验室,北京100044

出　　处：《中华肝脏病杂志》2022年第11期1137-1143,共7页Chinese Journal of Hepatology

摘　　要：随着丙型肝炎的治疗进入直接抗病毒药物时代, 获得治疗并实现病毒清除的患者越来越多, 但病毒清除只是一个相对终点, 治疗后的获益和临床结局演变将是今后关注的一个重点, 现描述病毒清除后尤其是直接抗病毒药物治疗的患者全因死亡, 肝病及肝外相关疾病的改善情况。As hepatitis C treatment entered the era of direct-acting antiviral drugs,an increasing number of patients received treatment and achieved virus clearance,but virus clearance is merely a relative endpoint.Future emphasis will be placed on post-treatment benefits and the evolution of clinical outcomes.This article aims to describe the improvement in all-cause mortality and hepatic and extrahepatic-related diseases following virus clearance,particularly in patients treated with direct-acting antiviral drugs.

关 键 词：丙型肝炎 直接抗病毒药物 肝细胞癌 门静脉高压 

分 类 号：R512.63[医药卫生—内科学]